NASDAQ · AUTL
Healthcare · Biotechnology
$1.79
Down-$0.04 (-2.19%)
Updated Oct 7, 2026, 7:54 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AUTL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AUTL closed at $1.79 after 21 trading sessions, down 15.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.84 | $1.87 | $1.764 | $1.79 | 1.68M |
| Oct 5, 2026 | $1.78 | $1.86 | $1.75 | $1.83 | 2.52M |
| Oct 2, 2026 | $1.85 | $1.88 | $1.76 | $1.78 | 1.81M |
| Oct 1, 2026 | $1.94 | $1.94 | $1.85 | $1.85 | 1.46M |
| Sep 30, 2026 | $1.88 | $1.99 | $1.865 | $1.94 | 1.16M |
| Sep 29, 2026 | $1.86 | $1.88 | $1.80 | $1.86 | 1.77M |
| Sep 28, 2026 | $1.82 | $1.8899 | $1.79 | $1.86 | 1.4M |
| Sep 25, 2026 | $1.91 | $1.9451 | $1.85 | $1.855 | 1.38M |
| Sep 24, 2026 | $1.95 | $1.9677 | $1.88 | $1.91 | 1.82M |
| Sep 23, 2026 | $2.04 | $2.05 | $1.92 | $1.95 | 1.44M |
| Sep 22, 2026 | $1.96 | $2.08 | $1.94 | $2.03 | 1.57M |
| Sep 21, 2026 | $1.95 | $1.96 | $1.91 | $1.94 | 1.1M |
| Sep 18, 2026 | $1.92 | $1.95 | $1.88 | $1.94 | 1.77M |
| Sep 17, 2026 | $1.915 | $1.95 | $1.89 | $1.92 | 1.09M |
| Sep 16, 2026 | $1.95 | $1.96 | $1.835 | $1.87 | 1.92M |
| Sep 15, 2026 | $1.95 | $1.959 | $1.875 | $1.89 | 978.73K |
| Sep 14, 2026 | $1.86 | $1.95 | $1.85 | $1.94 | 1.48M |
| Sep 11, 2026 | $1.98 | $1.98 | $1.87 | $1.88 | 1.72M |
| Sep 10, 2026 | $2.00 | $2.02 | $1.95 | $1.96 | 1.33M |
| Sep 9, 2026 | $2.10 | $2.10 | $2.02 | $2.03 | 1.72M |
| Sep 8, 2026 | $2.22 | $2.23 | $2.10 | $2.11 | 2.57M |
The latest Smart Investors Daily articles mentioning AUTL.
Company
Market Activity
Research & News
AUTL research
Company profile and research snapshot.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 9, 2026 | Needham | Buy | — |
| Mar 31, 2026 | Mizuho | Outperform | — |
| Mar 27, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 12, 2026
On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product revenue hit $45.7 million, up 119% from $20.9 million a year earlier and up from $26.2 million just one quarter prior. Management used the momentum to raise full-year 2026 guidance […]
Yahoo · Sep 9, 2026
Enrollment in LUMINA, the pivotal Phase 2 study of obe-cel in refractory lupus nephritis, is ongoingLONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to obecabtage
Benzinga · Sep 9, 2026
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026. LUMINA, the
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2026 Q2 earnings call.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AUTL.
